Fasting clinical trials

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

This study is testing a new drug, OKN4395, alone and with an existing cancer treatment, pembrolizumab, for various solid tumours. The main goals are to check its safety, how well it's tolerated, and if it helps fight cancer.